7 In a 52-week study of 1,995 patients (modified intention-to-treat population) with type 2 diabetes taking up to three oral hypoglycemic agents and at an increased risk of cardiovascular events, tirzepatide was superior to insulin glargine at all three doses
Constipation patterns manifest as decreased bowel movement frequency, harder stool consistency, straining, or a sensation of incomplete evacuation
California Department of Health Care Services, Medi-Cal PDL update, 2026 Mounjaro (tirzepatide) is FDA-approved for glycemic control in adults with type 2 diabetes only
Major providers like United Healthcare, Blue Cross Blue Shield, and Cigna cover tirzepatide for eligible patients, and Medicare Part D plans and some Medicaid programs may also provide coverage
Your doctor mentions maintenance doses, but your insurance only approves three months at a time
NEJM Wadden TA et al